
|Videos|February 2, 2017
The Future of Immune Checkpoint Inhibition in Gastric and Esophageal Cancers
Author(s)Geoffrey Y. Ku, MD
Geoffrey Y. Ku, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of immune checkpoint inhibition in gastric and esophageal cancers.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
How the Immune System Drives Nerve Growth in TNBC
3
AMH Testing Predicts Chemotherapy Benefit in RxPONDER Breast Cancer
4
ASTRO Issues Updated Clinical Practice Guideline on RT for Pancreatic Cancer
5



































